We interviewed GraniteShares' CEO Will Rhind from New York, soon after they launched a suite of ETP's which allow you to invest in three different baskets of giant US tech stocks. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOpen Orphan Share News (ORPH)

Share Price Information for Open Orphan (ORPH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.00
Bid: 37.50
Ask: 38.50
Change: -0.25 (-0.65%)
Spread: 1.00 (2.67%)
Open: 38.50
High: 38.50
Low: 38.00
Yest. Close: 38.25
ORPH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

EXECUTIVE CHANGES: New Cenkos CEO gets FCA nod; Feedback hires CFO

EXECUTIVE CHANGES: New Cenkos CEO gets FCA nod; Feedback hires CFO

6 May 21 15:33

Open Orphan launches new data platform to combat infectious diseases

Open Orphan launches new data platform to combat infectious diseases

9 Apr 21 10:33

TRADING UPDATES: Renew to buy J Browne; Idox in good start to year

TRADING UPDATES: Renew to buy J Browne; Idox in good start to year

26 Mar 21 14:36

TRADING UPDATES: SpaceandPeople swings to loss in 2020 amid virus

TRADING UPDATES: SpaceandPeople swings to loss in 2020 amid virus

25 Mar 21 17:14

Open Orphan makes progress with Covid-19 characterisation study

(Sharecast News) - Specialist pharmaceutical services clinical research company Open Orphan updated the market on its world-first Covid-19 characterisation study on Thursday, reporting that the first three volunteers had now completed the quarantine phase.

25 Mar 21 15:34

IN BRIEF: Open Orphan wins new contract with Oxford BioTherapeutics

IN BRIEF: Open Orphan wins new contract with Oxford BioTherapeutics

9 Mar 21 14:31

Open Orphan subsidiary awarded contract with Oxford BioTherapeutics

(Sharecast News) - Specialist pharmaceuticals contract research organisation Open Orphan announced on Tuesday that its subsidiary Venn Life Sciences had been awarded a contract for a study with clinical-stage oncology company Oxford BioTherapeutics.

9 Mar 21 11:38

IN BRIEF: Open Orphan Covid Characterisation Study Gets Approval

IN BRIEF: Open Orphan Covid Characterisation Study Gets Approval

17 Feb 21 13:48

Open Orphan opens new quarantine clinic in Whitechapel

(Sharecast News) - Pharmaceutical services contract research organisation (CRO) Open Orphan has opened a new quarantine clinic in east London, it announced on Wednesday.

3 Feb 21 16:28

IN BRIEF: Open Orphan Launches New Quarantine Clinic In London

IN BRIEF: Open Orphan Launches New Quarantine Clinic In London

3 Feb 21 11:55

Open Orphan renews contract with Carna Biosciences

(Sharecast News) - Pharmaceutical services clinical research organisation Open Orphan announced a further contract renewal with Carna Biosciences on Monday, extending its integrated drug development consultancy services with Open Orphan subsidiary Venn Life Sciences.

1 Feb 21 13:20

IN BRIEF: Open Orphan Inks Contract Renewal With Carna Biosciences

IN BRIEF: Open Orphan Inks Contract Renewal With Carna Biosciences

1 Feb 21 11:54

IN BRIEF: Open Orphan Opens Two New Volunteer Recruitment Centres

IN BRIEF: Open Orphan Opens Two New Volunteer Recruitment Centres

20 Jan 21 21:16

Open Orphan confirms first volunteer dosing of needle-free Covid vaccine

(Sharecast News) - Specialist pharmaceutical services contract research organisation Open Orphan announced on Monday that the first volunteer had been dosed with the Codagenix needle-free intranasal Covid-19 vaccine, 'COVI-VAC'.

11 Jan 21 15:56

Open Orphan Doses First Volunteer In Needle Free Covid Vaccine Trial

Open Orphan Doses First Volunteer In Needle Free Covid Vaccine Trial

11 Jan 21 11:45

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.